Hyperkalemia
📧 Sign up to get email alerts when something new happens for Hyperkalemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2017-03-30Clinical Trial Update: Measurement of Serum Potassium Rate During Accidental Hypothermia. [NA]
This document is a clinical trial update about measuring the rate of serum potassium change during accidental hypothermia. It lists associat…
-
FDA label_change · 2016-12-01FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
The FDA approved a supplemental application for VelTassa (patiromer) submitted by Vifor Pharma, Inc.
-
FDA approval · 2016-11-25FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
The FDA has approved a supplemental application for VELTASSA (patiromer) filed by Vifor Pharma, Inc. VELTASSA is used to treat hyperkalemia.
-
FDA approval · 2016-06-16FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
FDA approved a supplemental application for VELTASSA (patiromer) from Vifor Pharma, expanding its labeling.
-
CLINICAL_TRIALS trial_result · 2016-05-13Clinical Trial Update: Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns [NA]
A completed clinical study evaluating how potassium levels from venous blood draws compare to heel-stick samples in infants and newborns in …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-05-10FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
FDA approved a supplemental application for VELTASSA (patiromer) submitted by Vifor Pharma, Inc.
-
FDA approval · 2016-02-18FDA Approved: SODIUM POLYSTYRENE SULFONATE — Original Application (Chartwell RX, LLC)
FDA approved an original ANDA for sodium polystyrene sulfonate from Chartwell RX, LLC, establishing a generic product for the treatment of h…
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) [Phase 2]
Phase 2 trial update for patiromer in treating hyperkalemia in patients with hypertension and diabetic nephropathy (AMETHYST-DN) completed w…
-
CLINICAL_TRIALS trial_result · 2015-12-15Clinical Trial Update: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) [Phase 3]
Phase 3 trial assessing efficacy and safety of patiromer for treating hyperkalemia in chronic kidney disease; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2015-12-15Clinical Trial Update: Evaluation of Patiromer in Heart Failure Patients [Phase 2]
Phase 2 trial evaluating patiromer in patients with hyperkalemia and heart failure has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2015-12-15Clinical Trial Update: An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis [Phase 2]
Phase 2 open-label study evaluating patiromer in participants on hemodialysis; terminated with posted results in 2015.
-
FDA approval · 2015-10-21FDA Approved: VELTASSA — Original Application (Vifor Pharma, Inc.)
FDA approved VELTASSA (patiromer) from Vifor Pharma via the original NDA for the treatment of hyperkalemia.
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions [NA]
Clinical trial evaluating a decision support system for quality assurance of potassium-increasing drug–drug interactions in hyperkalemia has…
-
FDA approval · 2015-04-26FDA Approved: KIONEX — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approves a supplemental application for KIONEX (sodium polystyrene sulfonate) submitted by ANI Pharmaceuticals, Inc.
-
FDA approval · 2014-11-28FDA Approved: SODIUM POLYSTYRENE SULFONATE — Original Application (SUNRISE PHARMACEUTICAL, INC.)
FDA approved Sunrise Pharmaceutical, Inc.'s original application for sodium polystyrene sulfonate, a resin used to treat hyperkalemia.
-
CLINICAL_TRIALS trial_result · 2014-10-03Clinical Trial Update: Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients [Phase 4]
Phase 4 trial evaluating the efficacy of sodium polystyrene sulfonate for treating hyperkalemia in pre-dialysis patients has completed.
-
CLINICAL_TRIALS trial_result · 2014-09-03Clinical Trial Update: Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia [Phase 4]
This Phase 4 trial evaluated the safety and efficacy of sodium polystyrene sulfonate in hyperkalemia. The study was terminated and results w…
-
FDA approval · 2014-03-19FDA Approved: SODIUM POLYSTYRENE SULFONATE — Original Application (PuraCap Laboratories, LLC)
FDA approved the original ANDA for Sodium polystyrene sulfonate from PuraCap Laboratories, LLC, providing a generic option for treating hype…
-
CLINICAL_TRIALS trial_result · 2013-05-15Clinical Trial Update: Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years
A completed clinical trial evaluating the impact of dietary fiber intake on cardiovascular outcomes, potassium control, and lipid profile in…
-
FDA approval · 2012-09-25FDA Approved: SODIUM POLYSTYRENE SULFONATE — Supplemental Application (CMP Pharma, Inc.)
The FDA approved a supplemental application for CMP Pharma's sodium polystyrene sulfonate.
-
FDA approval · 2011-11-08FDA Approved: SODIUM POLYSTYRENE SULFONATE — Supplemental Application (KVK-Tech, Inc.)
The FDA approved a supplemental application for sodium polystyrene sulfonate by KVK-Tech, Inc. (ANDA 040905), marking an approved change rel…
-
FDA approval · 2011-06-24FDA Approved: SODIUM POLYSTYRENE SULFONATE — Supplemental Application (CMP Pharma, Inc.)
FDA approved a supplemental application for CMP Pharma's sodium polystyrene sulfonate under an ANDA, signaling an updated or expanded approv…
-
FDA approval · 2011-03-03FDA Approved: SODIUM POLYSTYRENE SULFONATE — Supplemental Application (CMP Pharma, Inc.)
FDA approves CMP Pharma, Inc.'s supplemental application for Sodium Polystyrene Sulfonate under ANDA087859.
-
FDA approval · 2009-03-30FDA Approved: SODIUM POLYSTYRENE SULFONATE — Original Application (KVK-Tech, Inc.)
FDA approved the original application for sodium polystyrene sulfonate from KVK-Tech, Inc., enabling a generic product for treating hyperkal…
-
CLINICAL_TRIALS research · 2008-10-29Clinical Trial Update: Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation [NA]
A clinical trial update exploring genetic determinants of albuterol inhalation's effects on potassium and glucose, specifically its hypokale…